Journal of Multiple Sclerosis
ISSN - 2376-0389NLM - 101654564
David Alan Olges
School of Psychology and Counseling,
Regent University, Virginia Beach, VA 23464
Tanzania
Case Report
Apresoline Promoted Acrolein Reduction in Patient with Relapsing Remitting Multiple Sclerosis
Author(s): David Alan Olges and Vanessa Wyche GrahamDavid Alan Olges and Vanessa Wyche Graham
Background: Acrolein has been implicated as an irritating/exacerbating factor in animal models of relapsing-remitting multiple sclerosis. In animal studies, Apresoline (Hydralazine) has acted as a successful acrolein scavenging agent and resulted in reduced behavioral deficits and decreased myelin damage. It has been hypothesized that Apresoline would be equally successful as a disease modifying treatment for relapsing-remitting multiple sclerosis.
Objective: To describe the case of acrolein reduction in a patient with relapsing-remitting multiple sclerosis taking Apresoline.
Methods: Case study.
Results: The patient was diagnosed with relapsing-remitting multiple sclerosis and found to have an elevated level of acrolein. After 60 days of Apresoline treatment, the patient’s acrolein level.. View More»
